Prof. Fernando López-Ríos (NTRK CONNECT) has developed this resource with COR2ED.
Prof. Fernando López-Ríos (NTRK CONNECT) has developed this resource with COR2ED.
Fernando Lopez-Rios is the Chief of the Molecular Diagnostics Service at Hospital Universitario 12 de Octubre (Madrid) and Professor of Pathology at Universidad Complutense (Madrid).
Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at HM Hospitales (Spain) and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York).
He is the 2023 recipient of the Mary J. Matthews Pathology & Transitional Research Award (International Association for the Study of Lung Cancer, IASLC) and the Deputy Chair of the IASLC Pathology Committee.
His main clinical and research expertise is in cancer biomarker testing.
Honoraria: AbbVie, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, MSD, Pfizer, Regeneron, Roche, and Thermo Fisher.
Research support: AstraZeneca, Janssen, Lilly, Pfizer, Roche, and Thermo Fisher.
Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers
Optimising 1st line TROP2 ADC decisions in metastatic triple-negative breast cancer